Laronidase biosimilar (CinnaGen)

拉罗尼酶生物类似药 (CinnaGen)

Report date: 2024/07/03 21:31:43

Base Information

Drug NameLaronidase biosimilar (CinnaGen)
Drug Alias NameP-046
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionAlpha-L-iduronidase replacements
TargetsAlpha-L-iduronidaseDermatan sulfateHeparan sulfate
Therapy Area/IndicationsMucopolysaccharidosis I
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIran
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesCinnagen
China Registration ClassN/A

Develop Information

Active CompaniesCinnagen
Inactive CompaniesN/A
Active IndicationsMucopolysaccharidosis I
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A